` PNV (Polynovo Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

PNV
vs
S&P/ASX 300

Over the past 12 months, PNV has underperformed S&P/ASX 300, delivering a return of -47% compared to the S&P/ASX 300's 9% growth.

Stocks Performance
PNV vs S&P/ASX 300

Loading
PNV
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
PNV vs S&P/ASX 300

Loading
PNV
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
PNV vs S&P/ASX 300

Loading
PNV
S&P/ASX 300
Add Stock

Competitors Performance
Polynovo Ltd vs Peers

S&P/ASX 300
PNV
ALC
7741
COLO B
ALGN
Add Stock

Polynovo Ltd
Glance View

Economic Moat
Narrow
Market Cap
832.5m AUD
Industry
Health Care

Polynovo Ltd. engages in the provision biodegradable medical devices. The company is headquartered in Melbourne, Victoria and currently employs 122 full-time employees. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. The company can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.

PNV Intrinsic Value
0.753 AUD
Overvaluation 38%
Intrinsic Value
Price
Back to Top